Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special use results survey for interstitial lung disease of ENHERTU FOR INTRAVENOUS DRIP INFUSION 100mg in unresectable advanced or recurrent gastric cancer patients

Next Previous
Search
Trial Profile

Special use results survey for interstitial lung disease of ENHERTU FOR INTRAVENOUS DRIP INFUSION 100mg in unresectable advanced or recurrent gastric cancer patients

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Company

    • Most Recent Events

    • 27 Feb 2024 New trial record
    • 20 Jan 2024 Interim results of post-marketing surveillance evaluating risk of ILD among patients with gastric cancer treated with T-DXd in a real-world setting, presented at the 2024 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top